A single center, randomized, open-label, crossover, single oral dose study to assess the bioequivalence of LAF237 [Vildagliptin] tablet manufactured by Beijing Novartis Pharma Ltd. to imported LAF237 tablet in Chinese healthy subjects

Trial Profile

A single center, randomized, open-label, crossover, single oral dose study to assess the bioequivalence of LAF237 [Vildagliptin] tablet manufactured by Beijing Novartis Pharma Ltd. to imported LAF237 tablet in Chinese healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 21 Jun 2007 Status change from in progress to completed
    • 11 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top